Full history for every metric is available with a Kvantra account
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €bn | 18 | 20 | 22 | 21 | 21 | 21 | 21 | 21 |
| Operating profit | €bn | 4 | 4 | ||||||
| Net profit | €bn | 2 | 3 | 3 | 3 | 3 | 3 | 2 | 4 |
| EPS reported | € | 6.00 | 5.45 | ||||||
| Operating cashflow per share | € | 9.04 | 9.73 | ||||||
| Capex per share | € | 3.64 | 3.66 | ||||||
| FCF per share | € | 5.40 | 6.08 | ||||||
| Free cash flow | €bn | 2 | 3 | ||||||
| Net debt | €bn | 8 | 10 | ||||||
| Book value equity | €bn | 29 | 30 | ||||||
| Book value per share | € | 65.76 | 69.40 | ||||||
| Number of shares | m | 434.78 | 434.78 | ||||||
| DPS (TTM paid) | € | 2.20 | 2.20 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 20.43 | 25.12 | ||||||
| P/B LTM | x | 1.86 | 1.97 | ||||||
| P/S LTM | x | 2.53 | 2.81 | ||||||
| P/FCF LTM | x | 22.70 | 22.51 | ||||||
| EV/EBITDA LTM | x | 11.47 | 11.01 | ||||||
| EV/Sales LTM | x | 2.96 | 3.30 | ||||||
| Earnings Yield LTM | % | 4.89% | 3.98% | ||||||
| FCF Yield | % | 4.40% | 4.44% | ||||||
| Quality | |||||||||
| ROE | % | 9.12% | 8.08% | ||||||
| ROIC | % | 7.26% | 7.17% | ||||||
| Operating margin | % | 19.26% | 19.68% | ||||||
| Gross margin | % | 56.35% | 58.69% | ||||||
| FCF/Sales | % | 11.13% | 12.50% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -6.10% | -17.17% | ||||||
| Sales Growth YoY | % | -0.26% | -0.40% | ||||||
| Net Income Growth YoY | % | -6.09% | -17.16% | ||||||
| FCF Growth | % | -2.25% | +48.34% | ||||||
| Operating Profit Growth | % | -6.92% | -8.51% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 1.95% | 1.61% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | 39.83% | 43.78% | ||||||
| FCF/Debt | x | 0.20 | 0.21 | ||||||
| Net Debt/EBITDA | x | 1.69 | 1.63 | ||||||
| EBIT/Net interest | x | 15.52 | 8.52 | ||||||
| Net debt/market cap | % | 15.75% | 17.40% | ||||||
| Net debt/Equity | x | 0.29 | 0.34 | ||||||
| Gross debt/equity | x | 0.42 | 0.41 | ||||||
ETFs that hold Merck
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| First Eagle Overseas Equity ETF | FEOE | 6 | 2.45% |
Funds with Merck among their ten largest holdings, largest fund first.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Merck KGaA is a German science and technology company with operations divided into three core segments: Life Science, Healthcare, and Electronics. The Life Science division supplies essential tools, chemicals, and equipment to academic research institutions, biotechnology firms, pharmaceutical manufacturers, and various industrial sectors. It also offers specialized process development expertise, such as continuous bioprocessing for drug manufacturers, provides a range of testing kits, reagents, and services, and develops solutions for analyzing environmental samples like air, water, and soil. Furthermore, this segment aids in assessing nutritional value and identifying quality control issues. In its Healthcare segment, the company is involved in the entire lifecycle of prescription drugs and biopharmaceuticals, from initial discovery and development through manufacturing and marketing. Its therapeutic focus areas include oncology, neurology and immunology, fertility, endocrinology, cardiovascular diseases, diabetes, thyroid disorders, and multiple sclerosis. This segment also produces general medicines, injection devices, and software for disease monitoring. The Electronics division delivers critical materials for the semiconductor and display industries. It also specializes in surface design, providing delivery systems and services, along with a variety of surface solutions for applications such as cosmetics, effect pigments, and other functional materials. Merck KGaA is also actively engaged in strategic partnerships. These include in-licensing agreements with Debiopharm International SA for developing treatments for head and neck cancer, with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for metastatic colorectal cancer drug candidates, and with Abbisko Therapeutics Co. Ltd. for therapies targeting tenosynovial giant cell tumors. Additionally, the company is involved in collaborations focused on discovering and developing targeted protein degraders against critical oncogenic proteins. Founded in 1668 and headquartered in Darmstadt, Germany, Merck KGaA operates as a subsidiary of E. Merck KG.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| First Eagle Overseas Equity ETF | FEOE | 6 | 2.45% |
Funds with Merck among their ten largest holdings, largest fund first.
Based on consensus from external analysts. Not Kvantra's opinion.
Merck KGaA is a German science and technology company with operations divided into three core segments: Life Science, Healthcare, and Electronics. The Life Science division supplies essential tools, chemicals, and equipment to academic research institutions, biotechnology firms, pharmaceutical manufacturers, and various industrial sectors. It also offers specialized process development expertise, such as continuous bioprocessing for drug manufacturers, provides a range of testing kits, reagents, and services, and develops solutions for analyzing environmental samples like air, water, and soil. Furthermore, this segment aids in assessing nutritional value and identifying quality control issues. In its Healthcare segment, the company is involved in the entire lifecycle of prescription drugs and biopharmaceuticals, from initial discovery and development through manufacturing and marketing. Its therapeutic focus areas include oncology, neurology and immunology, fertility, endocrinology, cardiovascular diseases, diabetes, thyroid disorders, and multiple sclerosis. This segment also produces general medicines, injection devices, and software for disease monitoring. The Electronics division delivers critical materials for the semiconductor and display industries. It also specializes in surface design, providing delivery systems and services, along with a variety of surface solutions for applications such as cosmetics, effect pigments, and other functional materials. Merck KGaA is also actively engaged in strategic partnerships. These include in-licensing agreements with Debiopharm International SA for developing treatments for head and neck cancer, with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for metastatic colorectal cancer drug candidates, and with Abbisko Therapeutics Co. Ltd. for therapies targeting tenosynovial giant cell tumors. Additionally, the company is involved in collaborations focused on discovering and developing targeted protein degraders against critical oncogenic proteins. Founded in 1668 and headquartered in Darmstadt, Germany, Merck KGaA operates as a subsidiary of E. Merck KG.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free